High Quality Content by WIKIPEDIA articles! Human Stem Cells Institute OJSC (HSCI) (Институт Стволовых Клеток Человека or "ИСКЧ") Russia’s first public biotech company. HSCI engages in development as well as commercialization and marketing of innovative products and services in the areas of cell-based, gene and post-genome technologies. As of today, HSCI Group projects encompass four core focus areas: regenerative medicine, bio-insurance, genetic medicine and biopharmaceuticals. HSCI owns the largest family cord blood stem cells bank in Russia – Gemabank®. In September 2012 Neovasculgen®, the first-in-class gene-therapy drug developed by HSCI for treatment of Peripheral Arterial Disease, went on sales in Russia. Starting January 2012, HSCI has begun actively promoting its new Gemascreen project - medical genetic diagnostics and consulting services provided by the Company throughout Russia with the aim of early detection, prevention and treatment of inherited diseases. In December 2010...

В наличии:
	Books.Ru - 1128 руб.	Перейти
Под заказ:
	OZON.ru - 1125 руб.	Перейти

Рейтинг книги: 4 из 5, 7 голос(-ов).